For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histologic confirmation of adenocarcinoma of the prostate

          -  Evidence of stage IV disease on previous bone, CT, and/or MRI scan

          -  Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone
             (GnRH) analogue or bilateral orchiectomy

          -  Mandatory plasma and fresh or archival tumor tissue must be submitted

        Exclusion Criteria:

          -  Prior malignancy active within the previous 3 years except for locally curable cancers
             that have been apparently cured, such as basal or squamous cell skin cancer,
             superficial bladder cancer, or carcinoma in situ of the breast

          -  Participants with active brain metastases

          -  Participants must have recovered from the effects of major surgery requiring general
             anesthesia or significant traumatic injury at least 14 days before treatment arm
             assignment

        Other protocol defined inclusion/exclusion criteria could apply